PubMed Health⌕ Search

PubMed · 15811309

[Brain synaptogenesis and epigenesis].

Abstract

Synaptic plasticity, or epigenesis, is present and varies throughout the whole life of the cerebral cortex. The adult synapse is formed of large and variable proteins assemblies acting as molecular switches leading to many distinct functional states. In the flow of activity circulating through the synaptic circuits, these multiple synaptic states transitions are modulated by the levels and sequences of activations of the pre- and post-synaptic domains. The efficiency of synaptic transmission is also modulated by competition and/or cooperativity with neighbouring synapses, and by many neuromodulations. Some transitions eventually lead to synaptogenesis. In the adult cerebral cortex, synaptogenesis remains a local event; axonal and dendritic arbors are not reshaped. On the contrary, during pre- and post-natal synaptogenesis, the same molecular mechanisms lead to a significant reorganization of the axonal and dendritic arbors. Early in the development, synapses are generated and differentiate under the control of robust mechanisms governed by genes. Then, during the critical periods, extending from the end of gestation to the end of puberty, the refinement of the synaptic architecture becomes experience-expectant. This "epigenetic opening" of synaptogenesis to environment is maximal in the human brain. It is the source of the exceptional cognitive adaptability of our species, and possibly one of its major fragility. Epigenetic manipulations of these critical periods are undertaken, allowing restoration of synaptic plasticity also in the adult brain.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Jean-Pierre Bourgeois. 2005. [Brain synaptogenesis and epigenesis].. https://doi.org/10.1051/medsci%2F2005214428

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

A MAGIBU-based model for pediatric and juvenile CNS tumors: an in-house epigenetic decision-support framework compared with online DNA methylation classifiers.

Background: DNA methylation profiling is a tool that provides key support for central nervous system (CNS) tumor classification. However, diagnostically ambiguous pediatric cases may result in discordant outputs across classifiers. We developed MAGIBU, a cross-platform, projection-based framework that embeds individual methylomes into a fixed CNS reference landscape, ranking diagnostic entities by local epigenetic proximity to support clinician-led integrative diagnosis. Methods: As a proof-of-concept, we evaluated MAGIBU in eight morphologically challenging pediatric/juvenile CNS tumors with unresolved diagnoses after institutional and central pathology review. To establish a benchmark in the absence of a definitive histopathological ground truth, a consensus epigenetic reference was defined a priori for cases showing concordant results between the Heidelberg CNS Tumor Methylation Classifier and Methylscape Analysis. Comparisons were also performed with Epigenomic Digital Pathology (EpiDiP). To validate MAGIBU beyond this discovery cohort, performance was assessed at the family level across the CNS methylation spectrum (n = 678, 28 methylation families), on non-array platforms (whole-genome bisulfite sequencing and Oxford Nanopore), and in a focused analysis of the low-grade glioma and diffuse midline glioma compartment across four independent cohorts (n = 670). Results: In the discovery cohort, MAGIBU achieved high concordance with the consensus reference (Cohen's κ = 0.855), outperforming EpiDiP (κ = 0.278), which frequently placed low-grade tumors in proximity to higher-grade reference regions. Conclusions: MAGIBU provides a stable, quantitative differential diagnosis framework that mitigates the limitations of rigid categorical assignments. By leveraging a distance-based proximity metric, it offers a transparent decision-support tool that integrates effectively with clinical, radiological, and molecular data. While performance is inherently dependent on reference atlas composition, MAGIBU represents a robust complementary approach for the diagnostic workup of ambiguous CNS tumors.

Brain↗

1q21.1 distal copy number variants are associated with cerebral and cognitive alterations in humans.

Low-frequency 1q21.1 distal deletion and duplication copy number variant (CNV) carriers are predisposed to multiple neurodevelopmental disorders, including schizophrenia, autism and intellectual disability. Human carriers display a high prevalence of micro- and macrocephaly in deletion and duplication carriers, respectively. The underlying brain structural diversity remains largely unknown. We systematically called CNVs in 38 cohorts from the large-scale ENIGMA-CNV collaboration and the UK Biobank and identified 28 1q21.1 distal deletion and 22 duplication carriers and 37,088 non-carriers (48% male) derived from 15 distinct magnetic resonance imaging scanner sites. With standardized methods, we compared subcortical and cortical brain measures (all) and cognitive performance (UK Biobank only) between carrier groups also testing for mediation of brain structure on cognition. We identified positive dosage effects of copy number on intracranial volume (ICV) and total cortical surface area, with the largest effects in frontal and cingulate cortices, and negative dosage effects on caudate and hippocampal volumes. The carriers displayed distinct cognitive deficit profiles in cognitive tasks from the UK Biobank with intermediate decreases in duplication carriers and somewhat larger in deletion carriers-the latter potentially mediated by ICV or cortical surface area. These results shed light on pathobiological mechanisms of neurodevelopmental disorders, by demonstrating gene dose effect on specific brain structures and effect on cognitive function.

Brain↗